Forazapadin Expanded Access Policy
Satellos Bioscience, Inc. Last updated Oct. 6, 2026.
satellos.comCrawled Oct 31, 2026
Satellos Bioscience, Inc. Last updated Oct. 6, 2026.
Satellos is developing a regenerative approach for facioscapulohumeral muscular dystrophy (FSHD), designed to restore the body's natural ability to repair muscle.
Satellos studies forazapadin (SAT-3247) for Duchenne and facioscapulohumeral muscular dystrophy.
Satellos's pipeline of forazapadin clinical programs across Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy (FSHD).
Incorporating three decades of research in muscle stem cell biology, the MyoReGenX platform powers the discovery of small molecules with the potential to treat degenerative muscle diseases.
Satellos is focused on restoring muscle stem cell function to treat degenerative muscle diseases, including Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy (FSHD).
Satellos published research on human satellite cell dynamics in adult skeletal muscle myofibers.
Satellos published research on dystrophin expression in muscle stem cells and their division.
Satellos published research on EGFR-Aurka signaling in polarity and regeneration.
Satellos published a review on orienting muscle stem cells for regeneration in health, aging, and disease.
Satellos develops therapeutics to treat Duchenne muscular dystrophy and other degenerative muscle diseases.
Position Summary
Mr. Mostafa is an accomplished financial leader in strategic and financial planning in the pharmaceutical industry. Currently, Mr. Mostafa is the Chief
Mr. Berger has more than 25 years of experience in capital markets and financial analysis. He serves on the Board of Directors of BELLUS Health sold to GSK,
Mr. MacKay has led biotech companies as CEO for over 20 years and currently heads a Versant-backed stealth startup.
Dr. Iris Loew-Friedrich is a seasoned biotech and pharmaceutical executive with extensive experience in global drug development, regulatory affairs, corporate
Mr. Mark Nawacki is co-founder, president and former CEO of Searchlight Pharma. Mr. Nawacki brings more than two decades of experience across pharmaceuticals,
Ms. Brown is a seasoned executive leader with over 30 years of experience in the bio-pharma industry, holding key leadership roles in North America, Europe,
Satellos is a clinical-stage biotech developing therapies to enhance muscle regeneration in Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and other degenerative muscle diseases.
Satellos aims to regenerate muscle using small-molecule drugs for Duchenne and other muscle diseases.
Last updated August 20, 2025
Last Updated: May 20, 2025
Satellos Bioscience Inc. forms a scientific advisory board to investigate biological regeneration mechanisms in aging and neuroscience. The initiative aims to advance research in cellular repair and neural function. The board will guide the company’s focus on developing therapies targeting age-related decline and neurological disorders.
Satellos Bioscience assigns the International Nonproprietary Name (INN) **forazapadin** to its lead drug candidate, previously called SAT-3247. The orally administered small molecule targets degenerative muscle diseases by restoring muscle regeneration. The company specializes in clinical-stage drug development for life-improving therapies.
Satellos Bioscience Inc. releases its second-quarter 2026 financial results, detailing revenue growth and operational milestones. The company emphasizes advancements in its biotechnology pipeline, including progress on lead drug candidates. Satellos also highlights strategic partnerships and expanded research collaborations to accelerate development timelines.
Satellos Bioscience secures FDA Fast Track designation for its experimental therapy **SAT-3247**, targeting **Duchenne muscular dystrophy**. The designation accelerates clinical development for SAT-3247, a potential treatment addressing the rare genetic disorder. Satellos now advances toward pivotal trials under the expedited review pathway.
Satellos Bioscience secures **$57.2 million** through a public offering. The funding supports the company’s growth in bioscience innovation, though specific use cases or products are not detailed in the announcement.
Satellos Bioscience reports early functional improvements in a Phase 1b trial of its oral drug **SAT-3247**, an AAK inhibitor targeting muscle regeneration in **Duchenne muscular dystrophy**. The 28-day study of five adult patients (ages 20–27) shows potential benefits in **grip strength**, marking the first functional data for the candidate. The small molecule aims to restore muscle repair by addressing progressive muscle loss.